Careful Dose Escalation Improves Tolerability of Mirogabalin in Trigeminal Neuropathic Pain

Read full text Summarise with VIRAT
Authors: UCHINUMA Kotomi, YAMAZAKI Yoko, Ryoko Kurisu, TOMINAGA Hikari, Aki Kawauchi, MAEDA Shigeru
Cited by: 0
References: 23

Summary

No summary yet. VIRAT can read this paper and write a plain-language summary of its aim, methods, key findings and limitations.

Summarise with VIRAT Free to try with your Science Catalogs account.

Abstract

This retrospective, single-center study evaluated the analgesic effects and tolerability of mirogabalin in patients aged 18 years or older who were diagnosed with post-traumatic trigeminal neuropathic pain (PTNP). All the participants received mirogabalin between April 2022 and March 2024. Pain intensity was assessed using a visual analog scale (VAS) before and after treatment. Treatment effectiveness was defined as a ≥30% reduction in VAS score or voluntary discontinuation of dose escalation due to sufficient pain relief. Adverse reactions (ARs) were documented at each visit and potential predictors of treatment efficacy, including age, sex, disease duration, dose, and the presence of ARs, were analyzed.

Fields of Study & Subjects

Pain Mechanisms and Treatments Trigeminal Neuralgia and Treatments Pain Management and Treatment

Publication details

Journal / source
THE JOURNAL OF THE STOMATOLOGICAL SOCIETY JAPAN
Volume
93
Issue
1
Pages
46–54
Publication date
30 March 2026
Language
EN